Search
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental
MK-0482
go.drugbank.com/drugs/DB17453InvestigationalMK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
AG-24322
go.drugbank.com/drugs/DB13035InvestigationalAG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[L880,L42500,L42510] It is marketed under the brand name Diacomit. … Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.
Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14560ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Mixtures: VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADET, VAXİGRİP TETRA 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 1 ADETKIN-3248
go.drugbank.com/drugs/DB17587InvestigationalIt was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance
Streptococcus pneumoniae type 15b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10333ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETPradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedPradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. … It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Ammonia
go.drugbank.com/drugs/DB11118ApprovedInvestigationalIt is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. … It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis
Mixtures: Physician EZ Use Joint Tunnel and Trigger Kit, Physician EZ Use Joint Tunnel and Trigger KitProducts: Snap Labs 20-Count Ammonia InhalantsNalorphine
go.drugbank.com/drugs/DB11490ExperimentalVet approvedIt acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. … It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.